国際学会

口頭発表

2024年

1. Elucidation of the role of the p53 pathway in cancers that retain wild-type p53. Rieko Ohki. 11th China-US Forum on Frontiers of Cancer Research” & the 9th Zhengzhou International Medical Forum 2024年5月、Zhengzhou.

2023年

1. A novel extrinsic apoptosis pathway regulated via the p53-p53PAD7-Hippo-YAP/TAZ axis. Rieko Ohki. The 10th International MDM2 Workshop 2023年10月、東京.
2. Modified p53 pathway promotes the malignant progression of PanNET by activating the Akt pathway and altering metabolism. Yu Chen. The 10th International MDM2 Workshop 2023年10月、東京.

2022年

1. Elucidation of the role of the p53 pathway in pancreatic neuroendocrine tumor. Rieko Ohki. The 7th JCA-AACR Special Joint Conference 2022年7月、京都.

2017年

1. PH domain-only protein PHLDA3 is a novel p53-regulated repressor of Akt and a novel tumor suppressor of neuroendocrine tumors-towards development of tailor-made therapies for neuroendocrine tumors- Rieko Ohki. The 22nd Korea-Japan Cancer Research Workshop 2017年12月、東京.
2. Identification of a novel p53 downstream pathway important in neuroendocrine tumor development. Rieko Ohki. p53 international workshop 2017年7月、シンガポール.

ポスター発表

2024年

1. Extrinsic induction of apoptosis and tumor suppression via the p53- p53PAD7-Hippo-YAP/TAZ-p73 pathway. Rieko Ohki, Masahiro Takikawa. 19th International p53 Workshop 2024年5月、イタリア、トリエステ.

2023年

1. A novel extrinsic apoptosis pathway regulated via the p53-p53PAD7-Hippo-YAP/TAZ axis. Masahiro Takikawa. The 10th International MDM2 Workshop 2023年10月、東京.
2. Medullary thyroid carcinoma, MTC, P53- PHLDA3, Rb, Stem cells, Undifferentiated state. Walied Kamel. The 10th International MDM2 Workshop 2023年10月、東京.
3. IER5 is required for ovarian cancer cell proliferation and peritoneal dissemination. Jayaraman Krishnaraj. The 10th International MDM2 Workshop 2023年10月、東京.

2022年

1. PHLDA3 suppresses the malignant progression of non-functional PanNET by regulating cell differentiation and metabolism. Yu Chen, Rieko Ohki. The 18th International p53 workshop at the Weizmann Institute of Science, Rehovot, Israel 2022年5月、イスラエル.

2021年

1. Akt dysregulation by loss of PHLDA3 is an important determinant of pancreatic neuroendocrine tumor progression. Yu Chen, Rieko Ohki. 1st JCA-AACR Precision Cancer Medicine International Symposium 2021年9月.（オンライン開催）

2020年

1. Investigating the crosstalk between MEN1, p53 and Notch reveals biomarkers of formation of primary pancreatic neuroendocrine tumors. Ylenia Capodanno, Y. Chen, N. Hiraoka, A. Yokoyama, J. Schrader, R. Ohki. The 17th Annual ENETS conference  2020年3月、スペイン、バルセロナ.

2017年

1. A p53 target gene IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumor progression. Shotaro Yamano, Yoshinori Asano, Tatsuya Kawase, Rieko Ohki. p53 international workshop 2017年7月、シンガポール.
2. PHLDA3 is a novel tumor suppressor of pituitary neuroendocrine tumors. Yu Chen, Maiko Minegishi, Kozue Saito, Benjamin Tycko, Syouzou Yamada, Hideo Namiki, Kentaro Semba, Rieko Ohki. p53 international workshop 2017年7月、シンガポール.